Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

Translational Oncology

Xiao Jiang¹  Xiaoxiong Wang²  Zhuzhong Cheng³  Chuan Li⁴  Shukui Zhou⁵  Zhifu Luo⁵  Hong Liao⁵  Xiaoai Wu⁵  Shirong Chen⁶  Taipeng Shen⁷  Shengke Yang⁷  Luzhou Liu⁷  Yutang Yao⁷  Xing Zhou⁷  Jiaqi Shen⁷  Ying Kou⁷  Zeng Li⁷ 

[1] Department of Radiology, Sichuan Province Maternal and Child Health Care Hospital, Chengdu 610041, China;Institute of Isotope, China Institute of Atomic Energy, Beijing 102413, China;Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China;Department of Radiology, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610041, China;Department of Urology, Sichuan Cancer Hospital, Chengdu 610041, China;Institute of Isotope, China Institute of Atomic Energy, Beijing 102413, China;Radiation Oncology Key Laboratory of Sichuan Province, PET/CT Centre, Sichuan Cancer Hospital, Chengdu 610041, China;

关键词: Prostate cancer;    Prostate-specific membrane antigen;    Biochemical recurrence;   

DOI  :  

来源: DOAJ

【 摘 要 】

Purpose: Prostate-specific membrane antigen (PSMA) ligands targeting has shown promising results in staging of prostate cancer (PCa). The aim of present study was to evaluate the value of 18F-PSMA-1007 PET/CT in PCa patients with biochemical recurrence. Methods: 71 patients with PCa after radical prostatectomy (RP) were included in the present study. Median prostate-specific antigen (PSA) level was 1.27 ng/mL (range 0.01–67.40 ng/mL, n = 69). All patients underwent whole-body PET/CT imaging after injection of 333±38 MBq 18F-PSMA-1007. The distribution of PSMA-positive lesions was assessed. The influence of PSA level, androgen deprivation therapy and primary Gleason score on PSMA-positive finding and uptake of 18F-PSMA-1007 were evaluated. Results: 56 (79%) patients showed at least one pathological finding on 18F-PSMA-1007 PET/CT. The rates of positive scans were 50%, 80%, 100%, 100% among patients with PSA levels ≤0.5, 0.51–1.0, 1.1–2.0 and >2.0 ng/mL, respectively. The median Gleason score was 8 (range 7–10), and higher Gleason score (≤7 vs. ≥8) leads to higher detection rates (58.3% (14/24) vs. 88.9% (32/36), P = 0.006). The median SUVmax of positive findings in patients with PSA levels ≤0.5, 0.51–1.0, 1.1–2.0 and >2.0 ng/mL were 4.51, 4.27, 11.50 and 14.08, respectively. The median SUVmax in patients with PSA level >2.0 ng/mL was significantly higher than that in patients with PSA ≤2.0 ng/mL (14.08 vs. 6.13, P<0.001). Conclusion: 18F-PSMA-1007 PET/CT demonstrated a high detection rate for patients with a raised PSA level after radical prostatectomy even in patients with extremely low PSA level (eg. PSA level ≤0.5 ng/mL), which was essential for further clinical management for PCa patients.

【 授权许可】

Unknown